Metformin and pancreatic neuroendocrine tumors: A systematic review and meta-analysis

doi:10.3748/wjg.v30.i7.759

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 30, Issue 7

This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (1393)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-3) series, Tables (1-2) series.

Item

Count

PDF

HTML

773

Figures (1-3)

Tables (1-2)

Sum=990

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

127

Download

276

Sum=403

Feb 21, 2024 (publication date) through Dec 23, 2024

Times Cited of This Article

Times Cited (1)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Meta-Analysis

World J Gastroenterol. Feb 21, 2024; 30(7): 759-769
Published online Feb 21, 2024. doi: 10.3748/wjg.v30.i7.759

Open in New Tab Full Size Figure Download Figure

Figure 1 PRISMA 2020 flow diagram. Selection of studies to review the diagnostic and prognostic value of type 2 diabetes mellitus and metformin for predicting the insurgence and post-treatment outcome of pancreatic neuroendocrine tumor.

Open in New Tab Full Size Figure Download Figure

Figure 2 Association between type 2 diabetes mellitus and pancreatic neuroendocrine tumor. A: Forest plots of hazard ratios and 95%CIs for the association between type 2 diabetes mellitus (T2DM) and pancreatic neuroendocrine tumor (pNET) diagnosis; B: Forest plots of hazard ratios and 95%CIs for the association between T2DM and pNET tumor-free survival.

Open in New Tab Full Size Figure Download Figure

Figure 3 Heterogenity of the studies exploring the association between type 2 diabetes mellitus and pancreatic neuroendocrine tumor. A and B: Galbraith plot (A) and Funnel plot (B) reporting the heterogeneity of the studies exploring the association between type 2 diabetes mellitus (T2DM) and pancreatic neuroendocrine tumor (pNET) diagnosis; C and D: Galbraith plot (C) and Funnel plot (D) reporting the heterogeneity of the studies exploring the association between T2DM and pNET tumor-free survival.

Citation: Cigrovski Berkovic M, Coppola A, Sesa V, Mrzljak A, Lai Q. Metformin and pancreatic neuroendocrine tumors: A systematic review and meta-analysis. World J Gastroenterol 2024; 30(7): 759-769
URL: https://www.wjgnet.com/1007-9327/full/v30/i7/759.htm
DOI: https://dx.doi.org/10.3748/wjg.v30.i7.759